ADMA Biologics Inc (ADMA) Receives Consensus Recommendation of “Buy” from Analysts

ADMA Biologics Inc (NASDAQ:ADMA) has been given an average recommendation of “Buy” by the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have covered the stock in the last year is $10.50.

A number of analysts have weighed in on ADMA shares. Oppenheimer set a $13.00 price target on ADMA Biologics and gave the company a “buy” rating in a research report on Wednesday, September 5th. Maxim Group upped their price target on ADMA Biologics from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, July 26th. BidaskClub upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd. Raymond James set a $10.00 price target on ADMA Biologics and gave the company a “buy” rating in a research report on Friday. Finally, Chardan Capital started coverage on ADMA Biologics in a research report on Monday, July 30th. They issued a “buy” rating and a $10.00 price target on the stock.

Shares of NASDAQ ADMA opened at $5.23 on Friday. The company has a debt-to-equity ratio of 0.79, a current ratio of 10.65 and a quick ratio of 8.88. The firm has a market capitalization of $287.83 million, a P/E ratio of -2.74 and a beta of 2.35. ADMA Biologics has a one year low of $2.01 and a one year high of $6.96.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Friday, August 10th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). ADMA Biologics had a negative net margin of 119.34% and a negative return on equity of 89.78%. The company had revenue of $4.66 million during the quarter, compared to the consensus estimate of $5.35 million. Equities analysts anticipate that ADMA Biologics will post -1.31 EPS for the current year.

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. grew its position in ADMA Biologics by 59.5% in the first quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 15,115 shares during the period. Spark Investment Management LLC grew its position in ADMA Biologics by 68.7% in the second quarter. Spark Investment Management LLC now owns 37,460 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 15,260 shares during the period. AMP Capital Investors Ltd bought a new stake in shares of ADMA Biologics during the second quarter worth $109,000. Element Capital Management LLC bought a new stake in shares of ADMA Biologics during the first quarter worth $118,000. Finally, Renaissance Technologies LLC bought a new stake in shares of ADMA Biologics during the second quarter worth $132,000. Hedge funds and other institutional investors own 55.08% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Featured Article: How is inflation measured?

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply